Top

Published in:

01-05-2004 | Observation

Unexpected elevation of pentosidine formation in collagen incubated with glucose by low concentrations of the AGE-inhibitor aminoguanidine

Authors: P. Urios, A.-M. Grigorova-Borsos, M. Sternberg

Published in: Diabetologia | Issue 5/2004

Excerpt

To the Editor: In diabetes, protein modification by hyperglycaemia leads to Amadori products like HbA₁c, which in turn can be oxidised to form advanced glycation end products (AGE), and particularly pentosidine [1]. Pentosidine cross-links peptidic chains, alters physicochemical properties of proteins and contributes to the development of diabetic complications. Skin collagen pentosidine levels, adjusted for age, have been shown to correlate with the severity of complications in Type 1 diabetic patients [2]. More recently, when adjusted for age and diabetes duration, they were significantly associated with nephropathy and neuropathy [3]. …

Monnier V, Fogarty JF, Monnier CS, Sell DR (1999) Glycation, glycoxidation and other Maillard reaction products. In: Byung PY (ed) Methods in aging research. CRC Press, Washington DC, pp 657–681

Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41:870–880

Monnier VM, Bautista O, Kenny D et al. (1999) Skin collagen glycation, glycoxidation, and cross-linking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA₁c as markers of diabetic complications. Diabetes 48:870–880

Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629–1632PubMed

Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31–40CrossRefPubMed

Woessner JF (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93:440–447

Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276:48967–48972CrossRefPubMed

Urios P, Borsos A-M, Garaud J, Feing-Kwong-Chan S, Sternberg M (2002) At low concentration, aminoguanidine markedly increases pentosidine formation in collagen incubated with glucose, whereas decreasing it at high level. In: Horiuchi S et al. (eds) The Maillard Reaction in Food Chemistry and Medial Science: update for the postgenomic era. Exerpta Medica International Congress Series, Amsterdam, p 413

Culbertson SM, Vassilenko EI, Morrison LD, Ingold KU (2003) Paradoxical impact of antioxidants on post-Amadori glycoxidation: Counterintuitive increase in the yields of pentosidine and N-epsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J Biol Chem 278:38384–38394CrossRefPubMed

10.

Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995) Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34:3702–3709PubMed

11.

Bucala R, Makita Z, Vega G et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441–9445PubMed

12.

Brown CD, Zhao ZH, Thomas LL, De Groof R, Friedman EA (2001) Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. Am J Kidney Dis 38:1414–1420PubMed

13.

Freedman BI, Wuerth J-P, Cartwright K et al. (1999) Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy. Control Clin Trials 20:493–510CrossRefPubMed

Title: Unexpected elevation of pentosidine formation in collagen incubated with glucose by low concentrations of the AGE-inhibitor aminoguanidine
Authors: P. Urios
A.-M. Grigorova-Borsos
M. Sternberg
Publication date: 01-05-2004
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 5/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1399-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Unexpected elevation of pentosidine formation in collagen incubated with glucose by low concentrations of the AGE-inhibitor aminoguanidine

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2004

Abnormal splicing of hepatocyte nuclear factor-1 beta in the renal cysts and diabetes syndrome

Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes

Is “Cushing’s disease of the omentum” an affliction of mouse and men?

Changes in expression of IL-1β influenced proteins in transplanted islets during development of diabetes in diabetes-prone BB rats

Control of glycaemia: from molecules to men. Minkowski Lecture 2003

Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page